Early-phase clinical trials exploring the use of anti-androgen agents, such as enzalutamide and bicalutamide, have shown promising results in AR-positive breast cancer subtypes, particularly those with a poor prognosis [70,71,72,73]. The gene discussed is AR; the disease is breast cancer.